See the full story in the original article.
Read the original on MarketWatch ↗
Keywords
Modernapharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related news
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Moderna shares plunge after leak of partial cancer vaccine data despite positive results
Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
Related markets
Latest news
- Meet Wall Street's Newest Major Stock Split: It Has Soared 1,730% Since Its 2012 IPO, and There Is Plenty of Upside Left
Meta Platforms announced a stock split with its third-quarter results, creating a non-voting Class C stock with one new share for each existing share, which the company says will help raise capital without diluting CEO Mark Zuckerberg's voting control. Revenue rose 26% year over year to $64.6 billion and EPS reached $3.83, up 265%, while operating income fell 37% to about $13 billion because of a $9.89 billion legal charge; excluding that charge, it would have risen 11%. The charge relates to a settlement of up to $18 billion over 10 years with a bipartisan group of state attorneys general over lawsuits about harm from its social media platforms. Daily active people rose 3% to 3.64 billion, and more than 10 million people in the U.S. and Canada have set up the Muse AI agent, with about 25% using it on any given day. The article says Meta's AI push could diversify its revenue, though its core advertising business still generates most of it.
- Wall Street Assets Take Nearly A Quarter Of Crypto Perpetual Trading: Glassnode Report
Bitcoin fell to $80,000 as traditional assets such as stocks, ETFs, indices, gold and oil took a bigger share of trading on crypto exchanges. According to a Glassnode and Fasanara Digital report, perpetual futures tied to these assets made up 23.5% of volume in August, up from 0.5% in November 2025, with about $778 billion traded in August alone. Trading in crypto-asset perpetuals fell 49% over the same period, which lifted the traditional-asset share. Binance handled about 55% of perpetual volume, OKX a little over 15% and Hyperliquid 11%, with traditional assets making up 35.2% of Hyperliquid's perpetual volume compared with 27.6% on Binance. The report says Bitcoin's correlation with gold peaked on September 11 at its highest level since data began in March 2018, and that the figures are conservative because unclassified contracts were counted as crypto.
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
Wall Street struggled last week as concerns about financing the AI boom overshadowed strong earnings. Meta reported negative free cash flow for the first time since its 2012 IPO, and CoreWeave fell 10% Thursday as investors scrutinized its borrowing costs, before the Dow dropped more than 1% Friday as oil surged on fears of renewed U.S. strikes against Iran. For the week, the Dow gained 0.4%, the S&P 500 fell 0.5% and the Nasdaq slipped 0.7%. The portfolio bought 10 shares of GE Vernova and upgraded it to a buy-equivalent 1 rating, while reducing broader AI exposure by exiting Broadcom at an average gain of roughly 128% and trimming CrowdStrike, which had a gain of about 187%. Defensive stocks like Kimberly-Clark (up 4.3%) and Home Depot (up 3.3%) benefited, while Meta, down more than 9% for the week, kept a hold-equivalent 2 rating and $800 price target.
- Could Redwire Be the Next Rocket Lab?
This article compares Redwire (RDW) with Rocket Lab (RKLB), after Rocket Lab pushed the first Neutron rocket launch to 2027 and its stock fell more than 20%. Redwire supplies space technology such as ROSA deployable solar arrays and has expanded into defense after acquiring Edge Autonomy, with Stalker and Penguin uncrewed aerial systems. In Q2, revenue rose around 90% year over year to $117.1 million and contracted backlog reached $542.1 million, while management reiterated full-year revenue guidance of $450 million to $500 million. The stock trades at over 6.3 times sales versus about 50 times for Rocket Lab, and 11 analysts rate Redwire a Moderate Buy, with price targets implying potential upside of up to 851% over the next year. The article also flags execution risks such as delays, cost overruns and competition, and says the key test is turning growth into sustainable profits and cash flow.
- Sweden's Government Offices Block ChatGPT and Claude, Keep Microsoft Copilot
Sweden’s Government Offices will block ChatGPT and Claude on staff computers from October 26, making Microsoft Copilot the only approved AI tool after a dedicated security review, according to Sveriges Radio. Director of digitalisation Mikael Wettercrantz said using AI services without a formal contract can have consequences for information security, citing several problematic uses involving sensitive information. Sweden’s Tax Agency and the National Board of Institutional Care have already imposed similar bans, and the Enforcement Authority is preparing its own decision. Some employees can still reach ChatGPT and Claude through an internal AI platform, though the scope and restrictions have not been disclosed. The article notes that Microsoft added Claude models to Copilot in early 2026, and the government has not confirmed whether that option is switched on in its Copilot instance.
- California Diesel Averages $8 . 242 as Tandon Blames Iran War
Republican congressional candidate Ritesh Tandon says President Donald Trump's Iran war has raised fuel costs, with California diesel averaging $8.242 per gallon in the week of Oct. 19 versus $6.276 nationally, per the EIA. He links higher diesel prices to rising merchandise prices and pressure on households living paycheck to paycheck. The BLS reported the all-items CPI rose 0.6% in September and 3.7% over 12 months (up from 3.4% in August), with gasoline supplying more than half the monthly gain as its index rose 9.1%; the release did not measure how much inflation came from the Iran war. The EIA said Brent went from $72 a barrel at the start of July to above $100 by July 23, and U.S. distillate inventories were 13% below their 2021–2025 average for the week ending Sept. 25. Tandon said that if elected he would seek to stop the war and control inflation.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.